A New Era for Flu Prevention: First Genetic-Based Shot Approved
The United States has reached a milestone in public health with the approval of its very first mRNA-based influenza vaccine. This new option is designed specifically for older adults, aiming to change how we protect ourselves from the seasonal flu.
Federal regulators have cleared this new shot for individuals who are 50 years of age and older. The approval is split into two categories:
- Adults between the ages of 50 and 64 received standard approval.
- Adults aged 65 and older received an accelerated approval, which means the developer will need to gather more real-world data to confirm its benefits over time.
While having a new option is helpful, the most notable aspect of this vaccine is the technology used to create it, which could change how future vaccines are developed.
The Challenge of the Changing Flu Virus
The flu is much more than a simple cold. While many people recover quickly, influenza remains a serious health threat. Every year, the virus causes tens of thousands of deaths in the United States and hundreds of thousands of deaths worldwide. It also leads to millions of doctor visits and places a heavy burden on hospital systems.
Preventing the flu is difficult because the virus constantly changes. Every year, scientists must try to predict which strains of the virus will spread months before the flu season actually begins. If their predictions are accurate, traditional vaccines work well, sometimes reaching about 60% effectiveness. However, if the virus mutates unexpectedly, the vaccine becomes much less effective.
Traditional vaccines also face a manufacturing bottleneck. Most flu shots are made using fertilized chicken eggs. This process takes a long time, and sometimes the virus adapts to the eggs while growing. This slight change can make the final vaccine less of a match for the actual flu virus circulating in communities. The problem is so common that for an upcoming flu season, health officials had to update all three components of the standard flu shot to keep up with recent mutations.
How Genetic Instructions Speed Up Protection
The newly approved vaccine uses genetic technology instead of grown viruses. Instead of using chicken eggs to grow the virus, this method uses mRNA, which stands for messenger RNA.
This technology acts like a temporary instruction manual for your immune system. It delivers a set of instructions that tell your body how to build a harmless piece of the flu virus. Your immune system learns to recognize this harmless piece and builds defenses against it.
Because these instructions are written in genetic code, scientists can update the recipe very quickly. This allows manufacturers to wait longer before choosing which flu strains to target, reducing the risk of a mismatch when flu season arrives. The platform pairs this adaptability with evidence that it can perform well compared to standard flu vaccines.
Strong Results in Clinical Testing
This new shot was tested in a large study involving more than 40,000 adults aged 50 and older. Half of the group received the new genetic-based shot, while the other half received a standard flu shot.
During the study, researchers tracked how many people got sick with lab-confirmed influenza during a recent winter flu season:
- In the group that received the new vaccine, about 2.0% (411 people) got sick.
- In the group that received the traditional vaccine, about 2.8% (557 people) got sick.
This represents a 26.6% relative difference in protection for those who received the new shot compared to the standard option. The new vaccine also showed promising signs of reducing severe illness. Only 22 people who got the new shot developed severe flu symptoms, compared to 42 people in the traditional group. While this is a relative difference of nearly 48%, the total number of severe cases was too small to draw a final statistical conclusion.
Looking Toward the Future of Vaccines
The success of this technology could open the door to even more convenient health options. For example, researchers are working to combine protection against both the flu and the coronavirus into a single annual shot. An earlier attempt to get a combination shot approved was delayed because regulators wanted more proof that the flu portion worked well. The success of this new vaccine provides the necessary evidence to help move those combination projects forward.
However, patients might not see this new shot everywhere right away. While some doses may become available at select pharmacies in the near future, most health systems and clinics purchase their flu shots many months in advance. It may take some time before this new option is widely available at every local clinic.
For decades, fighting the flu has been a race against time, requiring scientists to make early guesses and rely on slow manufacturing methods. This new approval shows that genetic technology can successfully enter that race and offer a faster, more adaptable way to help protect public health.